Abafungin

Abafungin

Abafungin

Chemical compound


Abafungin (INN) is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.

Quick Facts Clinical data, Trade names ...

Abasol is a topical cream formulation of abafungin by York Pharma.[1]

History

Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H2-antagonists related to famotidine, resulted in the discovery of its antifungal properties.[2]

Its development seems to have been discontinued in 2009.[3]

Mechanism of action

Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[2]

In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[4]

Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[5]


References

  1. "Regulatory Update – Abasol" (PDF). York Pharma. Archived from the original (PDF) on September 27, 2007.
  2. "Abafungin". AdisInsight. Retrieved 5 May 2021.
  3. Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, Ortiz A, Egido J (December 1995). "ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis". Kidney International. 48 (6): 1778–91. doi:10.1038/ki.1995.476. PMID 8587237.
  4. Ginter-Hanselmayer G (March 2009). Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten. Österreichische Apothekerkammer. p. 103.
  • Media related to Abafungin at Wikimedia Commons



Share this article:

This article uses material from the Wikipedia article Abafungin, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.